Xenon Pharmaceuticals
XENE
26 hedge funds and large institutions have $55.4M invested in Xenon Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
13% more funds holding
Funds holding: 23 → 26 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less capital invested
Capital invested by funds: $75.2M → $55.4M (-$19.7M)
Top Buyers
Top Sellers
XENE Hedge Fund Activity: Q2 2015 in Review
26 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2015, worth a combined $55.4M — down 26% from $75.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new XENE positions and 5 closed out — a net gain of 3 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was BVF Inc, adding an estimated $3.97M. The largest seller was Ativo Capital Management, exiting entirely with an estimated $2.32M sold.
- 26 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2015, up from 23 in Q1 2015.
- Funds reported $55.4M of Xenon Pharmaceuticals stock for Q2 2015, down 26% quarter-over-quarter.
- 8 funds opened new Xenon Pharmaceuticals positions in Q2 2015 and 5 closed out, a net change of +3 holders.
- The largest Xenon Pharmaceuticals buyer in Q2 2015 was BVF Inc, an estimated $3.97M added.
- The largest Xenon Pharmaceuticals seller in Q2 2015 was Ativo Capital Management, an estimated $2.32M sold.
Based on aggregated 13F filings for Q2 2015.